Global Regenerative Medicines Market – Analysis and Forecast (2017-2025) (Focus on Therapy, Applications, Market Share Analysis, 22 Country Analysis, and Competitive Landscape)
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Due to the fall of the fertility rates, and increased life expectancy, the world population is ageing rapidly. The prevalence of diseases such as diabetes, osteoarthritis, cardiovascular diseases, Alzheimer’s, and many others, are higher among the elderly. As per the Arthritis Foundation, the older population in the U.S. affected by arthritis is estimated to grow to 21% by 2040, from the current value of 15%. The rising prevalence of chronic diseases is another factor contributing to the growth of the market. In the recent years, the prevalence of chronic diseases has been increasing irrespective of the age. As per WHO, the global prevalence of diabetes increased to 8.5% in adults over the age of 18 years in 2014 from 4.7% in 1980. The prevalence of genetic diseases, and cancer has also witnessed a rise in the recent years.
Regenerative medicine presents with opportunities to change the treatment options, and offers complete cure of the diseases. The pharmaceutical industry is witnessing the growth of pipeline of candidates for regenerative medicine. A number of companies are now indulging in the research and development of such therapies.
The regenerative medicine market includes various cellular, and acellular products. The market involves various therapies such as gene therapy, cell therapy, and tissue engineering. This therapy is being applied to a number of diseases, and therapeutic areas such as orthopaedic, cardiovascular, wound healing, diabetes, neurodegenerative, immune-oncology, and others. The market analysis includes an in-depth examination of the key ecosystem players, and the key strategies and developments taking place in this market. Additionally, it includes market dynamics (market drivers, opportunities, and challenges), and industry analysis.
The purpose of the study is to gain a holistic view of the regenerative medicine market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the regenerative medicine market. The market has been segmented into ‘product’, ‘therapy’, ‘application’, and ‘geographical regions’. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market, and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into the consideration before entering the market.
This research report aims at answering various aspects of the global regenerative medicine market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global regenerative medicine market, and assesses the factors governing the same.
The answers to the following key questions can be derived from this report:
Due to the fall of the fertility rates, and increased life expectancy, the world population is ageing rapidly. The prevalence of diseases such as diabetes, osteoarthritis, cardiovascular diseases, Alzheimer’s, and many others, are higher among the elderly. As per the Arthritis Foundation, the older population in the U.S. affected by arthritis is estimated to grow to 21% by 2040, from the current value of 15%. The rising prevalence of chronic diseases is another factor contributing to the growth of the market. In the recent years, the prevalence of chronic diseases has been increasing irrespective of the age. As per WHO, the global prevalence of diabetes increased to 8.5% in adults over the age of 18 years in 2014 from 4.7% in 1980. The prevalence of genetic diseases, and cancer has also witnessed a rise in the recent years.
Regenerative medicine presents with opportunities to change the treatment options, and offers complete cure of the diseases. The pharmaceutical industry is witnessing the growth of pipeline of candidates for regenerative medicine. A number of companies are now indulging in the research and development of such therapies.
The regenerative medicine market includes various cellular, and acellular products. The market involves various therapies such as gene therapy, cell therapy, and tissue engineering. This therapy is being applied to a number of diseases, and therapeutic areas such as orthopaedic, cardiovascular, wound healing, diabetes, neurodegenerative, immune-oncology, and others. The market analysis includes an in-depth examination of the key ecosystem players, and the key strategies and developments taking place in this market. Additionally, it includes market dynamics (market drivers, opportunities, and challenges), and industry analysis.
The purpose of the study is to gain a holistic view of the regenerative medicine market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centred upon conducting a detailed study of the solutions allied with the regenerative medicine market. The market has been segmented into ‘product’, ‘therapy’, ‘application’, and ‘geographical regions’. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market, and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into the consideration before entering the market.
This research report aims at answering various aspects of the global regenerative medicine market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global regenerative medicine market, and assesses the factors governing the same.
The answers to the following key questions can be derived from this report:
- What are the major market drivers, challenges, and opportunities in the global regenerative medicine market?
- How did the regenerative medicine market evolve, and what is its scope in the future?
- What is the market share of the leading segments, and sub-segments of the global regenerative medicine market in 2017 and 2025?
- How will each segment of the global regenerative medicine market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2025?
- What are the influencing factors that may affect the market share of the key players?
- How will the industry evolve during the forecast period 2017-2025?
- What are the key developmental strategies implemented by the key players to stand out in this market?
- What will be the growth rate of the tissue engineering segment during the forecast period?
- Which therapy segment is expected to register the highest CAGR for the regenerative medicine market?
- How has the market been segmented on the basis of application? Which application segment has the largest share, and growth rate in the regenerative medicine market?
- What will be the value of immune-oncology segment by 2025?
- Which geographical location will contribute to the highest sales of regenerative medicine?
EXECUTIVE SUMMARY
1 REPORT SCOPE
1.1 Scope of the Report
1.2 Global Regenerative Medicine Market Segmentation
1.3 Research Methodology
1.3.1. Data Triangulation
1.3.2. Key Data Points From Secondary Sources
1.3.3. Key Data Points From Primary Sources
1.3.4. Top-Down Approach (Segmental Analysis)
1.3.5. Bottom-Up Approach (Segmental Analysis)
1.3.6. Assumptions and Limitations
1.3.7. Data and Prediction Modelling
2 MARKET OVERVIEW
2.1. Introduction
2.2. Evolutionary History
2.3. Present And Future
3 MARKET DYNAMICS
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
4 COMPETITIVE LANDSCAPE
4.1. Share of Key Developments & Strategies
4.2. Market Share Analysis
4.3. Porter's Five Force Analysis
5 GLOBAL REGENERATIVE MEDICINES MARKET, BY THERAPY
5.1. Cell Therapy
5.2. Gene Therapy
5.3. Tissue Engineering
6 GLOBAL REGENERATIVE MEDICINES MARKET, BY PRODUCT (QUALITATIVE)
6.1. Introduction
6.2. Acellular Products
6.3. Cellular Products
6.4. Products
6.5. Pipeline Products
7 GLOBAL REGENERATIVE MEDICINES MARKET, BY APPLICATION
7.1. Introduction
7.2. Orthopaedic & Dental
7.3. Cardiology
7.4. Wound Healing
7.5. Diabetes
7.6. Immuno-Oncology
7.7. Others
8 GLOBAL REGENERATIVE MEDICINES MARKET, BY REGION
8.1. Introduction
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9 COMPANY PROFILES
9.1. Acelity
9.1.1. Overview
9.1.2. Product Portfolio
9.1.3. Financials
9.1.3.1. Financial Summary
9.1.4. Acelity: SWOT Analysis
9.2. Athersys, Inc.
9.2.1. Overview
9.2.2. Product Pipeline
9.2.3. Financials
9.2.3.1. Financial Summary
9.2.4. Athersys, Inc.: SWOT Analysis
9.3. Cellular Biomedicine Group, Inc.
9.3.1. Overview
9.3.2. Product Pipeline
9.3.3. Financials
9.3.4. Cellular Biomedicine Group, Inc.: SWOT Analysis
9.4. Cytori Therapeutics
9.4.1. Overview
9.4.2. Product Portfolio
9.4.3. Financials
9.4.3.1 Financial Summary
9.4.4. Cytori Therapeutics: SWOT Analysis
9.5. Integra Lifesciences Corporation
9.5.1. Overview
9.5.2 Product Portfolio
9.5.3. Financials
9.5.3.1. Financial Summary
9.5.4. Integra Lifesciences Corporation: SWOT Analysis
9.6. Mesoblast Limited
9.6.1. Overview
9.6.2. Product Portfolio
9.6.3. Financials
9.6.3.1. Financial Summary
9.6.4. Mesoblast Limited: SWOT Analysis
9.7. MiMedx Group Inc.
9.7.1. Overview
9.7.2. Product Portfolio
9.7.3. Financials
9.7.3.1. Financial Summary
9.7.4. MiMedx Group Inc.: SWOT Analysis
9.8. Novartis International AG
9.8.1. Overview
9.8.2. Product Portfolio
9.8.3. Financials
9.8.3.1 Financial Summary
9.8.4. Novartis International AG: SWOT Analysis
9.9. NuVasive, Inc.
9.9.1. Overview
9.9.2. Product Portfolio
9.9.3. Financials
9.9.3.1 Financial Summary
9.9.4. Nuvasive, Inc: SWOT Analysis
9.10. Organogenesis Inc.
9.10.1. Overview
9.10.2. Product Portfolio
9.10.3. Corporate Summary
9.10.4. Organogenesis Inc.: SWOT Analysis
9.11. OSIRIS THERAPEUTICS, INC.
9.11.1. Overview
9.11.2. Product Portfolio
9.11.3. Financials
9.11.3.1. Financial Summary
9.11.4. OSIRIS THERAPEUTICS, INC.: SWOT Analysis
9.12. STRYKER CORPORATION
9.12.1. Overview
9.12.2. Product Portfolio
9.12.3. Financials
9.12.3.1. Financial Summary
9.12.4. STRYKER CORPORATION: SWOT Analysis
9.13. TERUMO CORPORATION
9.13.1. Overview
9.13.2. Product Portfolio
9.13.3. Financials
9.13.3.1 Financial Summary
9.13.4. TERUMO CORPORATION: SWOT Analysis
9.14. TiGenix
9.14.1. Overview
9.14.2. Product Pipeline
9.14.3. Financials
9.14.3.1 Financial Summary
9.14.4. TiGenix: SWOT Analysis
9.15. Tissue Regenix
9.15.1. Overview
9.15.2. Product Portfolio & Product Pipeline
9.15.3. Financials
9.15.3.1. Financial Summary
9.15.4. Tissue Regenix: SWOT Analysis
9.16. Vericel Corporation
9.16.1. Overview
9.16.2. Product Portfolio
9.16.3. Financials
9.16.3.1. Financial Summary
9.16.4. Vericel Corporation: SWOT Analysis
9.17. ViaCyte, Inc.
9.17.1. Overview
9.17.2. Product Pipeline
9.17.3. Corporate Summary
9.17.4. ViaCyte, Inc.: SWOT Analysis
9.18. Zimmer Biomet Holdings Inc
9.18.1. Overview
9.18.2. Product Portfolio
9.18.3. Financials
9.18.3.1 Financial Summary
9.18.4. Zimmer Biomet Holdings Inc: SWOT Analysis
9.19. Anika Therapeutics
9.20. Capricor Therapeutics
9.21. COOK BIOTECH, INC.
9.22. Gamida Cell
9.23. Juno Therapeutics
1 REPORT SCOPE
1.1 Scope of the Report
1.2 Global Regenerative Medicine Market Segmentation
1.3 Research Methodology
1.3.1. Data Triangulation
1.3.2. Key Data Points From Secondary Sources
1.3.3. Key Data Points From Primary Sources
1.3.4. Top-Down Approach (Segmental Analysis)
1.3.5. Bottom-Up Approach (Segmental Analysis)
1.3.6. Assumptions and Limitations
1.3.7. Data and Prediction Modelling
2 MARKET OVERVIEW
2.1. Introduction
2.2. Evolutionary History
2.3. Present And Future
3 MARKET DYNAMICS
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
4 COMPETITIVE LANDSCAPE
4.1. Share of Key Developments & Strategies
4.2. Market Share Analysis
4.3. Porter's Five Force Analysis
5 GLOBAL REGENERATIVE MEDICINES MARKET, BY THERAPY
5.1. Cell Therapy
5.2. Gene Therapy
5.3. Tissue Engineering
6 GLOBAL REGENERATIVE MEDICINES MARKET, BY PRODUCT (QUALITATIVE)
6.1. Introduction
6.2. Acellular Products
6.3. Cellular Products
6.4. Products
6.5. Pipeline Products
7 GLOBAL REGENERATIVE MEDICINES MARKET, BY APPLICATION
7.1. Introduction
7.2. Orthopaedic & Dental
7.3. Cardiology
7.4. Wound Healing
7.5. Diabetes
7.6. Immuno-Oncology
7.7. Others
8 GLOBAL REGENERATIVE MEDICINES MARKET, BY REGION
8.1. Introduction
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9 COMPANY PROFILES
9.1. Acelity
9.1.1. Overview
9.1.2. Product Portfolio
9.1.3. Financials
9.1.3.1. Financial Summary
9.1.4. Acelity: SWOT Analysis
9.2. Athersys, Inc.
9.2.1. Overview
9.2.2. Product Pipeline
9.2.3. Financials
9.2.3.1. Financial Summary
9.2.4. Athersys, Inc.: SWOT Analysis
9.3. Cellular Biomedicine Group, Inc.
9.3.1. Overview
9.3.2. Product Pipeline
9.3.3. Financials
9.3.4. Cellular Biomedicine Group, Inc.: SWOT Analysis
9.4. Cytori Therapeutics
9.4.1. Overview
9.4.2. Product Portfolio
9.4.3. Financials
9.4.3.1 Financial Summary
9.4.4. Cytori Therapeutics: SWOT Analysis
9.5. Integra Lifesciences Corporation
9.5.1. Overview
9.5.2 Product Portfolio
9.5.3. Financials
9.5.3.1. Financial Summary
9.5.4. Integra Lifesciences Corporation: SWOT Analysis
9.6. Mesoblast Limited
9.6.1. Overview
9.6.2. Product Portfolio
9.6.3. Financials
9.6.3.1. Financial Summary
9.6.4. Mesoblast Limited: SWOT Analysis
9.7. MiMedx Group Inc.
9.7.1. Overview
9.7.2. Product Portfolio
9.7.3. Financials
9.7.3.1. Financial Summary
9.7.4. MiMedx Group Inc.: SWOT Analysis
9.8. Novartis International AG
9.8.1. Overview
9.8.2. Product Portfolio
9.8.3. Financials
9.8.3.1 Financial Summary
9.8.4. Novartis International AG: SWOT Analysis
9.9. NuVasive, Inc.
9.9.1. Overview
9.9.2. Product Portfolio
9.9.3. Financials
9.9.3.1 Financial Summary
9.9.4. Nuvasive, Inc: SWOT Analysis
9.10. Organogenesis Inc.
9.10.1. Overview
9.10.2. Product Portfolio
9.10.3. Corporate Summary
9.10.4. Organogenesis Inc.: SWOT Analysis
9.11. OSIRIS THERAPEUTICS, INC.
9.11.1. Overview
9.11.2. Product Portfolio
9.11.3. Financials
9.11.3.1. Financial Summary
9.11.4. OSIRIS THERAPEUTICS, INC.: SWOT Analysis
9.12. STRYKER CORPORATION
9.12.1. Overview
9.12.2. Product Portfolio
9.12.3. Financials
9.12.3.1. Financial Summary
9.12.4. STRYKER CORPORATION: SWOT Analysis
9.13. TERUMO CORPORATION
9.13.1. Overview
9.13.2. Product Portfolio
9.13.3. Financials
9.13.3.1 Financial Summary
9.13.4. TERUMO CORPORATION: SWOT Analysis
9.14. TiGenix
9.14.1. Overview
9.14.2. Product Pipeline
9.14.3. Financials
9.14.3.1 Financial Summary
9.14.4. TiGenix: SWOT Analysis
9.15. Tissue Regenix
9.15.1. Overview
9.15.2. Product Portfolio & Product Pipeline
9.15.3. Financials
9.15.3.1. Financial Summary
9.15.4. Tissue Regenix: SWOT Analysis
9.16. Vericel Corporation
9.16.1. Overview
9.16.2. Product Portfolio
9.16.3. Financials
9.16.3.1. Financial Summary
9.16.4. Vericel Corporation: SWOT Analysis
9.17. ViaCyte, Inc.
9.17.1. Overview
9.17.2. Product Pipeline
9.17.3. Corporate Summary
9.17.4. ViaCyte, Inc.: SWOT Analysis
9.18. Zimmer Biomet Holdings Inc
9.18.1. Overview
9.18.2. Product Portfolio
9.18.3. Financials
9.18.3.1 Financial Summary
9.18.4. Zimmer Biomet Holdings Inc: SWOT Analysis
9.19. Anika Therapeutics
9.20. Capricor Therapeutics
9.21. COOK BIOTECH, INC.
9.22. Gamida Cell
9.23. Juno Therapeutics
LIST OF TABLES
Global Regenerative Medicines Market (2016 & 2025)
Comparison of Regenerative Medicines Market: China vs U.S.
Key Regional Markets for Regenerative Medicines
Percentage of Total Regional Population Aged 65 Years & Above: 2015 & 2030
Market Share Analysis, 2015-2017
Factors Affecting the Bargaining Power of Suppliers
Factors Affecting the Bargaining Power of Buyers
Factors Affecting Threat of New Entrants
Factors Affecting the Threat of Substitutes
Factors Affecting the Intensity of Competitive Rivalry
Global Stem Cells Market, by Country, 2016-2025 ($Million)
Global Gene Therapy Market, by Country, 2016-2025 ($Million)
Global Tissue Engineering Market, by Product Type, 2016-2025 ($Million)
Global Tissue Engineering Market, by Country, 2016-2025 ($Million)
Some of the Approved Regenerative Medicine Products
Products In The Pipeline
Overview: Acelity
Overview: Athersys, Inc.
Overview: Cellular Biomedicine Group, Inc.
Product Pipeline: Cellular Biomedicine Group, Inc.
Overview: Cytori Therapeutics
Overview: Integra LifeSciences Corporation
Overview: Mesoblast
Product Portfolio: Mesoblast
Overview: MiMedx Group Inc.
Overview: Novartis International AG
Overview: NuVasive, Inc.
Overview: Organogenesis Inc.
Overview: OSIRIS THERAPEUTICS, INC.
Overview: Stryker Corporation
Overview: Terumo Corporation
Overview: TiGenix
Product Pipeline: TiGenix
Overview: Tissue Regenix
Overview: Vericel Corporation
Overview: ViaCyte, Inc.
Product Pipeline: ViaCyte, Inc.
Overview: Zimmer Biomet Holdings Inc.
Overview: Anika Therapeutics, Inc.
Overview: Capricor Therapeutics
Overview: COOK BIOTECH, INC.
Overview: Gamida Cell
Overview: Juno Therapeutics
Global Regenerative Medicines Market (2016 & 2025)
Comparison of Regenerative Medicines Market: China vs U.S.
Key Regional Markets for Regenerative Medicines
Percentage of Total Regional Population Aged 65 Years & Above: 2015 & 2030
Market Share Analysis, 2015-2017
Factors Affecting the Bargaining Power of Suppliers
Factors Affecting the Bargaining Power of Buyers
Factors Affecting Threat of New Entrants
Factors Affecting the Threat of Substitutes
Factors Affecting the Intensity of Competitive Rivalry
Global Stem Cells Market, by Country, 2016-2025 ($Million)
Global Gene Therapy Market, by Country, 2016-2025 ($Million)
Global Tissue Engineering Market, by Product Type, 2016-2025 ($Million)
Global Tissue Engineering Market, by Country, 2016-2025 ($Million)
Some of the Approved Regenerative Medicine Products
Products In The Pipeline
Overview: Acelity
Overview: Athersys, Inc.
Overview: Cellular Biomedicine Group, Inc.
Product Pipeline: Cellular Biomedicine Group, Inc.
Overview: Cytori Therapeutics
Overview: Integra LifeSciences Corporation
Overview: Mesoblast
Product Portfolio: Mesoblast
Overview: MiMedx Group Inc.
Overview: Novartis International AG
Overview: NuVasive, Inc.
Overview: Organogenesis Inc.
Overview: OSIRIS THERAPEUTICS, INC.
Overview: Stryker Corporation
Overview: Terumo Corporation
Overview: TiGenix
Product Pipeline: TiGenix
Overview: Tissue Regenix
Overview: Vericel Corporation
Overview: ViaCyte, Inc.
Product Pipeline: ViaCyte, Inc.
Overview: Zimmer Biomet Holdings Inc.
Overview: Anika Therapeutics, Inc.
Overview: Capricor Therapeutics
Overview: COOK BIOTECH, INC.
Overview: Gamida Cell
Overview: Juno Therapeutics
LIST OF FIGURES
Figure 1 Regenerative Medicines Industry Sectors
Figure 2 Regenerative Medicines in Healthcare system
Figure 3 The Global Regenerative Medicines Market ($Billion)
Figure 4 Key Opportunities
Figure 5 Impact Analysis
Figure 6 Chronic Conditions: Key Statistics: 2016
Figure 7 Global Regenerative Medicines Market, by Therapy Type ($Million)
Figure 8 Global Regenerative Medicines Market, by Therapy, 2016
Figure 9 Global Regenerative Medicines Market, by Therapy, 2025
Figure 10 Evolution of Tissue Engineered Products
Figure 11 Tissue Engineered Therapy Market, by Product Type ($Billion)
Figure 12 Global Regenerative Medicines Market, by Application, 2016
Figure 13 Global Regenerative Medicines Market, by Application, 2025
Figure 14 Global Regenerative Medicines Market Value, by Region, 2016 & 2025 ($Billion)
Figure 15 Global Regenerative Medicines Market, by Region, 2016
Figure 16 Global Regenerative Medicines Market, by Region, 2025
Figure 17 Competitive Landscape: Global Regenerative Medicines Market
Figure 18 Global Regenerative Medicines Market Share Analysis: 2016
Figure 19 Importance of sustainability criteria from a industry (Manufacturer) point of view
Figure 20 Global Regenerative Medicines Market Segmentation
Figure 21 Research Methodology
Figure 22 Data Triangulation
Figure 23 Key Data Points From Secondary Sources
Figure 24 Key Data Points From Primary Sources
Figure 25 Top-Down Approach (Segment wise Analysis)
Figure 26 Bottom-Up Approach (Segmental Analysis)
Figure 27 Assumptions and Limitations
Figure 28 Data and Prediction Modelling
Figure 29 Regenerative Medicine Types
Figure 30 Evolutionary History
Figure 31 The Present and Future of Regenerative Medicine
Figure 32 Market Dynamics
Figure 33 Share of Different Strategies in the Market
Figure 34 Porter’s Five Forces Analysis
Figure 35 Global Regenerative Medicines Market, By Therapy, 2016-2023 ($Million)
Figure 36 Some Of The Strategies Of Cell Therapy
Figure 37 Types of Cell Therapy
Figure 38 Types of Stem Cells
Figure 39 Global Stem Cell Market, 2016-2025 ($Billion)
Figure 40 Global Stem Cells Market, by Type, 2016-2025 ($Billion)
Figure 41 Cord Blood Banking Market, 2016-2025 ($Billion)
Figure 42 Stem Cells & Services Market, 2016-2025 ($Billion)
Figure 43 Global Stem Cell Therapies Market, 2016-2025 ($Billion)
Figure 44 Global Stem Cells Market, by region, 2016-2025 ($Million)
Figure 45 Types of Gene Therapy
Figure 46 Gene Therapy Techniques
Figure 47 Global Gene Therapy Market, 2016-2025 ($Million)
Figure 48 Global Gene Therapy Market, by Region, 2016-2025 ($Million)
Figure 49 Global Tissue Engineering Therapy Market, 2016-2025 ($Billion)
Figure 50 Global Bone, Tendon, Cartilage, Allograft, and Autografts Market, 2016-2025 ($Million)
Figure 51 Global Bone Graft Substitutes Market, 2016-2025 ($Million)
Figure 52 Global Bone Growth Factors and Spinal Stimulation Market, 2016-2025 ($Million)
Figure 53 Global Demineralised Bone Matrix Market, 2016-2025 ($Million)
Figure 54 Global Bone Morphogenetic Proteins Market, 2016-2025 ($Million)
Figure 55 Global Other Orthobiologics Market, 2016-2025 ($Million)
Figure 56 Global Platelet Rich Plasma Market, 2016-2025 ($Million)
Figure 57 Global Skin/Dermal Substitutes (Allo/Autografts) Market, 2016-2025 ($Million)
Figure 58 Global Bioengineered Skin/ Synthetic Substitutes Market, 2016-2025 ($Million)
Figure 59 Global Placenta/Amniotic Tissue Market, 2016-2025 ($Million)
Figure 60 Global Growth Factors Market, 2016-2025 ($Million)
Figure 61 Global Topical Biologics Market, 2016-2025 ($Million)
Figure 62 Global Tissue Heart Valves Market, 2016-2025 ($Million)
Figure 63 Global Vascular Synthetic Grafts and Patches Market, 2016-2025 ($Million)
Figure 64 Global Tissue Composits Market, 2016-2025 ($Million)
Figure 65 Global Others Market, 2016-2025 ($Million)
Figure 66 Types of Products
Figure 67 Global Regenerative Medicines Market, by Application
Figure 68 Global Regenerative Medicines Market, by Application, 2016-2025 ($Billion)
Figure 69 Types of Skin Regeneration
Figure 70 Types of Diabetes Mellitus
Figure 71 Regenerative Medicine In Oncology
Figure 72 Global Regenerative Medicines Market, by region
Figure 73 Global Regenerative Medicines Market, by region 2016-2025 ($Billion)
Figure 74 The U.S. Regenerative Medicines Market, 2016-2025 ($Million)
Figure 75 The U.S. Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 76 Canada Regenerative Medicines Market, 2016-2025 ($Million)
Figure 77 Canada Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 78 Germany Regenerative Medicines Market, 2016-2025 ($Million)
Figure 79 Germany Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 80 France Regenerative Medicines Market, 2016-2025 ($Million)
Figure 81 France Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 82 Italy Regenerative Medicines Market, 2016-2025 ($Million)
Figure 83 Italy Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 84 The U.K. Regenerative Medicines Market, 2016-2025 ($Million)
Figure 85 The U.K. Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 86 Spain Regenerative Medicines Market, 2016-2025 ($Million)
Figure 87 Spain Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 88 Netherlands Regenerative Medicines Market, 2016-2025 ($Million)
Figure 89 The Netherlands Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 90 Belgium Regenerative Medicines Market, 2016-2025 ($Million)
Figure 91 Belgium Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 92 Rest of Europe Regenerative Medicines Market, 2016-2025 ($Million)
Figure 93 Rest of Europe Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 94 Japan Regenerative Medicines Market, 2016-2025 ($Million)
Figure 95 Japan Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 96 China Regenerative Medicines Market, 2016-2025 ($Million)
Figure 97 China Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 98 South Korea Regenerative Medicines Market, 2016-2025 ($Million)
Figure 99 South Korea Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 100 Australia Regenerative Medicines Market, 2016-2025 ($Million)
Figure 101 Australia Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 102 India Regenerative Medicines Market, 2016-2025 ($Million)
Figure 103 India Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 104 Malaysia Regenerative Medicines Market, 2016-2025 ($Million)
Figure 105 Malaysia Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 106 Singapore Regenerative Medicines Market, 2016-2025 ($Million)
Figure 107 Singapore Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 108 Rest of Asia Regenerative Medicines Market, 2016-2025 ($Million)
Figure 109 Rest of Asia Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 110 Brazil Regenerative Medicines Market, 2016-2025 ($Million)
Figure 111 Brazil Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 112 Mexico Regenerative Medicines Market, 2016-2025 ($Million)
Figure 113 Mexico Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 114 Rest of LATAM Regenerative Medicines Market, 2016-2025 ($Million)
Figure 115 Rest of LATAM Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 116 KSA Regenerative Medicines Market, 2016-2025 ($Million)
Figure 117 KSA Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 118 Russia Regenerative Medicines Market, 2016-2025 ($Million)
Figure 119 Russia Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 120 Israel Regenerative Medicines Market, 2016-2025 ($Million)
Figure 121 Israel Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 122 The UAE Regenerative Medicines Market, 2016-2025 ($Million)
Figure 123 The UAE Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 124 Rest of World Regenerative Medicines Market, 2016-2025 ($Million)
Figure 125 Rest of World Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 126 Acelity: Product Portfolio
Figure 127 Acelity: SWOT Analysis
Figure 128 Athersys, Inc.: Product Pipeline
Figure 129 Athersys, Inc.: SWOT Analysis
Figure 130 Cellular Biomedicine Group, Inc.: SWOT Analysis
Figure 131 Cytori Therapeutics: Product Portfolio
Figure 132 Cytori Therapeutics: SWOT Analysis
Figure 133 Integra LifeSciences Corporation: Product Portfolio
Figure 134 Integra LifeSciences Corporation: SWOT Analysis
Figure 135 Mesoblast Limited: SWOT Analysis
Figure 136 MiMedx Group Inc.: Product Portfolio
Figure 137 MiMedx Group Inc.: SWOT Analysis
Figure 138 Novartis International AG: Product Portfolio
Figure 139 NuVasive, Inc.: Product Portfolio
Figure 140 NuVasive, Inc.: SWOT Analysis
Figure 141 Organogenesis Inc: Product Portfolio
Figure 142 Organogenesis Inc: SWOT Analysis
Figure 143 OSIRIS THERAPEUTICS, INC.: Product Portfolio
Figure 144 OSIRIS THERAPEUTICS, INC.: SWOT Analysis
Figure 145 STRYKER CORPORATION: Product Portfolio
Figure 146 STRYKER CORPORATION: SWOT Analysis
Figure 147 TERUMO CORPORATION: Product Portfolio
Figure 148 TERUMO CORPORATION: SWOT Analysis
Figure 149 TiGenix: Product Portfolio
Figure 150 TiGenix: SWOT Analysis
Figure 151 Tissue Regenix: Product Portfolio
Figure 152 Tissue Regenix Group plc: SWOT Analysis
Figure 153 Vericel Corporation: Product Portfolio
Figure 154 Vericel Corporation: SWOT Analysis
Figure 155 Zimmer Biomet Holdings Inc: Product Portfolio
Figure 156 Zimmer Biomet Holdings Inc: SWOT Analysis
Figure 1 Regenerative Medicines Industry Sectors
Figure 2 Regenerative Medicines in Healthcare system
Figure 3 The Global Regenerative Medicines Market ($Billion)
Figure 4 Key Opportunities
Figure 5 Impact Analysis
Figure 6 Chronic Conditions: Key Statistics: 2016
Figure 7 Global Regenerative Medicines Market, by Therapy Type ($Million)
Figure 8 Global Regenerative Medicines Market, by Therapy, 2016
Figure 9 Global Regenerative Medicines Market, by Therapy, 2025
Figure 10 Evolution of Tissue Engineered Products
Figure 11 Tissue Engineered Therapy Market, by Product Type ($Billion)
Figure 12 Global Regenerative Medicines Market, by Application, 2016
Figure 13 Global Regenerative Medicines Market, by Application, 2025
Figure 14 Global Regenerative Medicines Market Value, by Region, 2016 & 2025 ($Billion)
Figure 15 Global Regenerative Medicines Market, by Region, 2016
Figure 16 Global Regenerative Medicines Market, by Region, 2025
Figure 17 Competitive Landscape: Global Regenerative Medicines Market
Figure 18 Global Regenerative Medicines Market Share Analysis: 2016
Figure 19 Importance of sustainability criteria from a industry (Manufacturer) point of view
Figure 20 Global Regenerative Medicines Market Segmentation
Figure 21 Research Methodology
Figure 22 Data Triangulation
Figure 23 Key Data Points From Secondary Sources
Figure 24 Key Data Points From Primary Sources
Figure 25 Top-Down Approach (Segment wise Analysis)
Figure 26 Bottom-Up Approach (Segmental Analysis)
Figure 27 Assumptions and Limitations
Figure 28 Data and Prediction Modelling
Figure 29 Regenerative Medicine Types
Figure 30 Evolutionary History
Figure 31 The Present and Future of Regenerative Medicine
Figure 32 Market Dynamics
Figure 33 Share of Different Strategies in the Market
Figure 34 Porter’s Five Forces Analysis
Figure 35 Global Regenerative Medicines Market, By Therapy, 2016-2023 ($Million)
Figure 36 Some Of The Strategies Of Cell Therapy
Figure 37 Types of Cell Therapy
Figure 38 Types of Stem Cells
Figure 39 Global Stem Cell Market, 2016-2025 ($Billion)
Figure 40 Global Stem Cells Market, by Type, 2016-2025 ($Billion)
Figure 41 Cord Blood Banking Market, 2016-2025 ($Billion)
Figure 42 Stem Cells & Services Market, 2016-2025 ($Billion)
Figure 43 Global Stem Cell Therapies Market, 2016-2025 ($Billion)
Figure 44 Global Stem Cells Market, by region, 2016-2025 ($Million)
Figure 45 Types of Gene Therapy
Figure 46 Gene Therapy Techniques
Figure 47 Global Gene Therapy Market, 2016-2025 ($Million)
Figure 48 Global Gene Therapy Market, by Region, 2016-2025 ($Million)
Figure 49 Global Tissue Engineering Therapy Market, 2016-2025 ($Billion)
Figure 50 Global Bone, Tendon, Cartilage, Allograft, and Autografts Market, 2016-2025 ($Million)
Figure 51 Global Bone Graft Substitutes Market, 2016-2025 ($Million)
Figure 52 Global Bone Growth Factors and Spinal Stimulation Market, 2016-2025 ($Million)
Figure 53 Global Demineralised Bone Matrix Market, 2016-2025 ($Million)
Figure 54 Global Bone Morphogenetic Proteins Market, 2016-2025 ($Million)
Figure 55 Global Other Orthobiologics Market, 2016-2025 ($Million)
Figure 56 Global Platelet Rich Plasma Market, 2016-2025 ($Million)
Figure 57 Global Skin/Dermal Substitutes (Allo/Autografts) Market, 2016-2025 ($Million)
Figure 58 Global Bioengineered Skin/ Synthetic Substitutes Market, 2016-2025 ($Million)
Figure 59 Global Placenta/Amniotic Tissue Market, 2016-2025 ($Million)
Figure 60 Global Growth Factors Market, 2016-2025 ($Million)
Figure 61 Global Topical Biologics Market, 2016-2025 ($Million)
Figure 62 Global Tissue Heart Valves Market, 2016-2025 ($Million)
Figure 63 Global Vascular Synthetic Grafts and Patches Market, 2016-2025 ($Million)
Figure 64 Global Tissue Composits Market, 2016-2025 ($Million)
Figure 65 Global Others Market, 2016-2025 ($Million)
Figure 66 Types of Products
Figure 67 Global Regenerative Medicines Market, by Application
Figure 68 Global Regenerative Medicines Market, by Application, 2016-2025 ($Billion)
Figure 69 Types of Skin Regeneration
Figure 70 Types of Diabetes Mellitus
Figure 71 Regenerative Medicine In Oncology
Figure 72 Global Regenerative Medicines Market, by region
Figure 73 Global Regenerative Medicines Market, by region 2016-2025 ($Billion)
Figure 74 The U.S. Regenerative Medicines Market, 2016-2025 ($Million)
Figure 75 The U.S. Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 76 Canada Regenerative Medicines Market, 2016-2025 ($Million)
Figure 77 Canada Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 78 Germany Regenerative Medicines Market, 2016-2025 ($Million)
Figure 79 Germany Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 80 France Regenerative Medicines Market, 2016-2025 ($Million)
Figure 81 France Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 82 Italy Regenerative Medicines Market, 2016-2025 ($Million)
Figure 83 Italy Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 84 The U.K. Regenerative Medicines Market, 2016-2025 ($Million)
Figure 85 The U.K. Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 86 Spain Regenerative Medicines Market, 2016-2025 ($Million)
Figure 87 Spain Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 88 Netherlands Regenerative Medicines Market, 2016-2025 ($Million)
Figure 89 The Netherlands Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 90 Belgium Regenerative Medicines Market, 2016-2025 ($Million)
Figure 91 Belgium Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 92 Rest of Europe Regenerative Medicines Market, 2016-2025 ($Million)
Figure 93 Rest of Europe Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 94 Japan Regenerative Medicines Market, 2016-2025 ($Million)
Figure 95 Japan Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 96 China Regenerative Medicines Market, 2016-2025 ($Million)
Figure 97 China Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 98 South Korea Regenerative Medicines Market, 2016-2025 ($Million)
Figure 99 South Korea Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 100 Australia Regenerative Medicines Market, 2016-2025 ($Million)
Figure 101 Australia Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 102 India Regenerative Medicines Market, 2016-2025 ($Million)
Figure 103 India Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 104 Malaysia Regenerative Medicines Market, 2016-2025 ($Million)
Figure 105 Malaysia Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 106 Singapore Regenerative Medicines Market, 2016-2025 ($Million)
Figure 107 Singapore Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 108 Rest of Asia Regenerative Medicines Market, 2016-2025 ($Million)
Figure 109 Rest of Asia Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 110 Brazil Regenerative Medicines Market, 2016-2025 ($Million)
Figure 111 Brazil Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 112 Mexico Regenerative Medicines Market, 2016-2025 ($Million)
Figure 113 Mexico Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 114 Rest of LATAM Regenerative Medicines Market, 2016-2025 ($Million)
Figure 115 Rest of LATAM Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 116 KSA Regenerative Medicines Market, 2016-2025 ($Million)
Figure 117 KSA Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 118 Russia Regenerative Medicines Market, 2016-2025 ($Million)
Figure 119 Russia Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 120 Israel Regenerative Medicines Market, 2016-2025 ($Million)
Figure 121 Israel Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 122 The UAE Regenerative Medicines Market, 2016-2025 ($Million)
Figure 123 The UAE Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 124 Rest of World Regenerative Medicines Market, 2016-2025 ($Million)
Figure 125 Rest of World Regenerative Medicines Market, by Therapy 2016-2025 ($Million)
Figure 126 Acelity: Product Portfolio
Figure 127 Acelity: SWOT Analysis
Figure 128 Athersys, Inc.: Product Pipeline
Figure 129 Athersys, Inc.: SWOT Analysis
Figure 130 Cellular Biomedicine Group, Inc.: SWOT Analysis
Figure 131 Cytori Therapeutics: Product Portfolio
Figure 132 Cytori Therapeutics: SWOT Analysis
Figure 133 Integra LifeSciences Corporation: Product Portfolio
Figure 134 Integra LifeSciences Corporation: SWOT Analysis
Figure 135 Mesoblast Limited: SWOT Analysis
Figure 136 MiMedx Group Inc.: Product Portfolio
Figure 137 MiMedx Group Inc.: SWOT Analysis
Figure 138 Novartis International AG: Product Portfolio
Figure 139 NuVasive, Inc.: Product Portfolio
Figure 140 NuVasive, Inc.: SWOT Analysis
Figure 141 Organogenesis Inc: Product Portfolio
Figure 142 Organogenesis Inc: SWOT Analysis
Figure 143 OSIRIS THERAPEUTICS, INC.: Product Portfolio
Figure 144 OSIRIS THERAPEUTICS, INC.: SWOT Analysis
Figure 145 STRYKER CORPORATION: Product Portfolio
Figure 146 STRYKER CORPORATION: SWOT Analysis
Figure 147 TERUMO CORPORATION: Product Portfolio
Figure 148 TERUMO CORPORATION: SWOT Analysis
Figure 149 TiGenix: Product Portfolio
Figure 150 TiGenix: SWOT Analysis
Figure 151 Tissue Regenix: Product Portfolio
Figure 152 Tissue Regenix Group plc: SWOT Analysis
Figure 153 Vericel Corporation: Product Portfolio
Figure 154 Vericel Corporation: SWOT Analysis
Figure 155 Zimmer Biomet Holdings Inc: Product Portfolio
Figure 156 Zimmer Biomet Holdings Inc: SWOT Analysis
